What is one of the first-line treatments for hyperkalemia?

Kayexalate, also known as sodium polystyrene sulfonate, is a commonly used treatment for hyperkalemia because it works by exchanging sodium ions for potassium ions in the intestines, effectively reducing serum potassium levels. This mechanism makes it valuable for managing elevated potassium levels in patients who cannot immediately undergo dialysis or in acute management scenarios.

While other treatments for hyperkalemia have their roles, such as calcium gluconate that stabilizes myocardial cells and decreases the risk of cardiac arrhythmias associated with high potassium levels, it does not directly reduce serum potassium. Furosemide, a loop diuretic, can promote renal excretion of potassium but may not be effective in patients with impaired kidney function. Bicarbonate, while it can shift potassium into cells temporarily, is not a primary treatment for lowering potassium levels and is usually reserved for specific cases, like metabolic acidosis.

Thus, the focus on Kayexalate as a first-line treatment arises from its ability to actively lower systemic potassium rather than just its effects on cardiac stabilization or short-term shifts.